Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 1INTERVENTIONAL

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Who May Be Eligible (Plain English)

Key Who May Qualify: - Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer - Able to take oral medication - If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements - your organs (liver, kidneys, etc.) are working well enough based on blood tests and electrolytes Key Who Should NOT Join This Trial: - Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812 - Impaired cardiac function - Major surgery within 28 days of the first dose of study drug Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Key Inclusion Criteria: * Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer * Able to take oral medication * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements * Adequate organ function and electrolytes Key Exclusion Criteria: * Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812 * Impaired cardiac function * Major surgery within 28 days of the first dose of study drug

Treatments Being Tested

DRUG

DCC-2812

Administered orally

Locations (3)

Dana-Farber Cancer Institute
Boston, Massachusetts, United States
NEXT Oncology, Austin
Austin, Texas, United States
NEXT Oncology, San Antonio
San Antonio, Texas, United States